Trends in Psoriatic Arthritis Management From 1993 to 2019: Rise of Biologics and Decline of Oral Small Molecules

Biologics have increasingly replaced traditional OSMs as the primary treatment for PsA. The decline in combination therapy after 2013 likely reflects the improved efficacy of newer biologics, reducing the need for adjunctive OSM use. Limitations include the lack of disease severity data and the absence of visits for newer therapies, such as Janus kinase inhibitors.